Summary of Product Characteristics (SmPC) - Sodium Cromoglicate 100 mg hard capsules
1 NAME OF THE MEDICINAL PRODUCT
Sodium Cromoglicate 100mg hard Capsules
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each capsule contains 100mg Sodium Cromoglicate
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Hard capsules (capsules)
Transparent capsule with circular double band on body and cap, containing white to off-white powder.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Food allergy (where adequate investigations have been performed to determine sensitivity to one or more ingested allergens) in conjunction with restriction of main causative allergens.
4.2 Posology and method of administration
Posology
Adults (including the elderly)
Initial dose: 2 capsules four times daily before meals
Children (2 - 14 years)
Initial dose: 1 capsule four times daily before meals
For adults (including the elderly) and children, if satisfactory control is not achieved within two to three weeks, the dosage may be doubled but should not exceed 40 mg/Kg/day.
Maintenance dose: Once a therapeutic response has been achieved, the dose may be reduced to the minimum required to maintain the patient free from symptoms.
Method of administration
Sodium Cromoglicate must be administered orally
4.3 Contraindications
Contraindicated in patients with a known hypersensitivity to Sodium Cromoglicate or to any of the excipients.
4.4 Special warnings and precautions for use
None Stated.
4.5 Interaction with other medicinal products and other forms of interaction
None known.
4.6 Fertility, Pregnancy and lactation
As with all medication caution should be exercised especially during the first trimester of pregnancy. Cumulative experience with Sodium Cromoglicate suggests that it has no adverse effects on foetal development. It should only be used in pregnancy where there is a clear need.
It is not known whether Sodium Cromoglicate is excreted in the breast milk but on the basis of its physico-chemical properties this is considered unlikely. There is no information to suggest that the use of Sodium Cromoglicate has any undesirable effects on the baby.
4.7 Effects on ability to drive and use machines
None known.
4.8 Undesirable effects
Nausea, skin rashes and joint pains have been reported in a few cases.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9 Overdose
As Sodium Cromoglicate is only absorbed to a minimum extent, no action other than medical supervision should be necessary.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Antiallergic agents, excluding corticosteroids, ATC Code: A07EB01
Sodium Cromoglicate inhibits the release from mast cells of mediators of the allergic reaction. In gastrointestinal allergy the release of mediators can result in gastrointestinal symptoms or may allow absorption of antigenic material leading to systemic allergic reactions.
5.2 Pharmacokinetic properties
Not Applicable.
5.3 Preclinical safety data
Animal studies have shown that sodium cromoglicate has a very low order of local or systemic toxicity.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Capsule Shell
Gelatin
Printing Ink
Shellac
Propylene Glycol
Black iron Oxide (E172)
Potassium Hydroxide
6.2 Incompatibilities
None Stated
6.3 Shelf life
36 months
After first opening: 1 month
6.4 Special precautions for storage
Keep the bottle tightly closed in order to protect from moisture.
6.5 Nature and contents of container
White opaque HDPE container with child resistant closure containing 100 capsules.
6.6 Special precautions for disposal
Any unused medicinal product should be disposed of in accordance with local requirements
7 MARKETING AUTHORISATION HOLDER
Strandhaven Limited t/a Somex Pharma
Ilford
Essex
IG3 8BS.UK.
8 MARKETING AUTHORISATION NUMBER(S)
PL 15764/0161
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
01/03/2016 / 18/02/2025
10 DATE OF REVISION OF THE TEXT
28/06/2022